Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins

Journal of Virology

Volumn 72, Issue 7, 1998, Pages 5441-5448

  Kobinger, Gary P ^a   Borsetti, Alessandra ^b   Nie, Zilin ^a   Mercier, Johanne ^a   Daniel, Nesrine ^a   Göttlinger, Heinrich G ^b   Cohen, Éric A ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VPR FUSION PROTEIN;

ARTICLE; GENE EXPRESSION; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; VIRION; VIRUS GENE; VIRUS INACTIVATION; VIRUS REPLICATION;

EID: 0031799928     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.7.5441-5448.1998     Document Type: Article

References (41)

1. Baltimore, D. 1988. Intracellular immunization. Nature (London) 335:395-396.
2. Bevec, D., M. Dobrovnik, J. Hauber, and E. Böhnlein. 1992. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative rev trans-activator. Proc. Natl. Acad. Sci. USA 89:9870-9874.
3. Boeke, J. D., and B. Hahn. 1996. Destroying retroviruses from within. Trends Microbiol. 4:421-426.
4. Bonyhadi, M. L., K. Moss, A. Voytovich, J. Auten, C. Kalfoglou, I. Plavec, S. Forestall, L. Su, E. Böhnlein, and H. Kaneshima. 1997. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem progenitor cells inhibit human immunodeficiency virus replication. J. Virol. 71: 4707-4716.
5. Camaur, D., and D. Trono. 1996. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70:6106-6111.
6. Cohen, E. A., G. Dehni, J. G. Sodroski, and W. A. Haseltine. 1990. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J. Virol. 64:3097-3099.
7. Cohen, E. A., E. F. Terwilliger, Y. Jalinoos, J. Proulx, J. G. Sodroski, and W. A. Haseltine. 1990. Identification of HIV-1 vpr product and function. J. Acquired Immune Defic. Syndr. 3:11-18.
8. Cohen, E. A., E. F. Terwilliger, J. G. Sodroski, and W. A. Haseltine. 1988. Identification of a protein encoded by the vpu gene of HIV-1. Nature (London) 334:532-534.
9. Collman, R., J. W. Balliet, S. A. Gregory, H. Friedman, D. L. Kolson, N. Nathanson, and A. Srinivasan. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66:7517-7521.
10. Danos, O., and R. C. Mulligan. 1988. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA 85:6460-6464.
11. Di Marzio, P., S. Choe, M. Ebright, R. Knoblauch, and N. R. Landau. 1995. Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 vpr. J. Virol. 69:7909-7916.
12. Einfeld, D. 1996. Maturation and assembly of retroviral glycoproteins, p. 133-176. In H.-G. Kräusslich (ed.), Morphogenesis and maturation of retroviruses, vol. 214. Springer-Verlag KG, Berlin, Germany.
13. Fletcher, M. T., M. A. Soares, S. McPhearson, H. Hui, M. Wiskerchen, M. A. Muesing, G. M. Shaw, A. D. Leavitt, J. D. Boeke, and B. H. Hahn. 1997. Complementation of integrase function in HIV-1 virions. EMBO J. 16:5123-5138.
14. Gilboa, E., and C. Smith. 1994. Gene therapy for infectious diseases: the AIDS model. Trends Genet. 10:139-144.
15. Goncalves, J., B. Shi, X. Yang, and D. Gabuzda. 1995. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J. Virol. 69:7196-7204.
16. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.
17. He, J., S. Choe, R. Walker, P. Di Marzio, D. O. Morgan, and N. R. Landau. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34-cdc2 activity. J. Virol. 69:6705-6711.
18. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line based on activation of an integrated beta-galactosidase gene. J. Virol. 66: 2232-2239.
19. Kondo, E., and H. G. Göttlinger. 1996. A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J. Virol. 70:159-164.
20. gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J. Virol. 69:2759-2764.
21. Krumlauf, R. 1996. Northern blot analysis. Methods Mol. Biol. 58:113-128.
22. gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles. J. Virol. 68:1926-1934.
23. gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J. Virol. 69: 6873-6879.
24. Mahalingam, S., V. Ayyavoo, M. Patel, T. Kieber-Emmons, and D. B. Weiner. 1997. Nuclear import, virion incorporation, and cell cycle arrest/ differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J. Virol. 71:6339-6347.
25. Mahalingam, S., M. Patel, R. G. Collman, and A. Srinivasan. 1995. The carboxy-terminal domain is essential for stability and not for virion incorporation of HIV-1 Vpr into virus particles. Virology 214:647-652.
26. Malim, M. H., S. Bohnlein, A. J. Hauber, and B. R. Cullen. 1989. Functional dissection of the HIV-1 rev trans-activator: derivation of the trans-dominant repressor of Rev function. Cell 58:205-214.
27. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
28. Matsuda, Z., X. Yu, Q.-C. Yu, T.-H. Lee, and M. Essex. 1993. A virion inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:3544-3548.
29. Miller, A. D. 1992. Human gene therapy comes of age. Nature (London) 357:455-460.
30. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587-3596.
31. Park, I. W., and J. Sodroski. 1996. Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus. J. Acquired Immune Defic. Syndr. 11:341-350.
32. 2 by inhibiting the activation of p34-cdc2-cyclin B. J. Virol. 69:6859-6864.
33. Serio, D., T. A. Rizvi, M. Cartas, V. S. Kalyanaraman, I. T. Weber, H. Koprowski, and A. Srinivasan. 1997. Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc. Natl. Acad. Sci. USA 94:3346-3351.
34. Vogt, V. M. 1996. Proteolytic processing and particle maturation, p. 95-131. In H.-G. Kräusslich (ed.), Morphogenesis and maturation of retroviruses, vol. 214. Springer-Verlag KG, Berlin, Germany.
35. Welker, R., H. Kottler, H. R. Kalbitzer, and H.-G. Kräusslich. 1996. Human immunodeficiency virus type 1 Nef protein is incorporated into the virus particles and specifically cleaved by the viral proteinase. Virology 219:228-236.
36. Woffendin, C., Z. Y. Yang, Udaykumar, L. Xu, N. S. Yang, M. J. Sheeny, and G. J. Nabel. 1994. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc. Natl. Acad. Sci. USA 91:11581-11585.
37. Wu, X., H. Liu, H. Xiao, J. A. Conway, E. Hunter, and J. C. Kappes. 1997. Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 16:5113-5122.
38. Wu, X., H. Liu, H. Xiao, J. A. Conway, and J. C. Kappes. 1996. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles. J. Virol. 70:3378-3384.
39. Wu, X., H. Liu, H. Xiao, and J. C. Kappes. 1996. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins. Virology 219:307-313.
40. Yao, X.-J., J. Friborg, F. Checroune, S. Gratton, F. Boisvert, R. P. Sékaly, and E. A. Cohen. 1995. Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity. Virology 209:615-623.
41. Yao, X. J., H. Göttlinger, W. A. Haseltine, and E. A. Cohen. 1992. Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export. J. Virol. 66:5119-5126.